Raymond Ernest Kaweesa

Dr. Raymond Ernest Kaweesa

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
JSJennifer Serwanga
Jennifer Serwanga
RKRaymond Ernest Kaweesa
Raymond Ernest Kaweesa
Joseph Ssebwana KatendeJoseph Ssebwana Katende
Joseph Ssebwana Katende
GOGeoffrey Odoch
Geoffrey Odoch
RWRaymond Reuel Wayesu
Raymond Reuel Wayesu
PKPontiano Kaleebu
Pontiano Kaleebu
Background: Marburg virus disease (MVD) is a highly lethal filoviral infection, yet its long-term health consequences remain poorly understood. We present one of the most temporally distant evaluations of MVD survivors, conducted 13 years post-outbreak in Uganda, offering novel insights into chronic physiological, biochemical, haematological, and psychosocial outcomes. Methods: A cross-sectional, community-based study compared ten MVD survivors with nineteen age- and sex-matched unexposed controls. Clinical evaluations included vital signs, anthropometry, mental health screening, and symptom reporting. Laboratory analyses covered electrolytes, inflammatory markers, renal and liver function tests, haematology, and urinalysis. Standardised psychological assessments measured anxiety, depression, perceived stigma, and social support. Findings: Survivors exhibited an elevated body mass index (BMI), higher systolic and diastolic blood pressure, and lower respiratory rates compared to controls, indicating ongoing cardiometabolic and autonomic changes. These trends may reflect persistent cardiometabolic stress and potential alterations in autonomic regulation, warranting further investigation. Biochemically, survivors exhibited disruptions in serum chloride, bilirubin, and total protein levels, suggesting subclinical hepatic and renal stress. Haematological analysis revealed persistent reticulocytosis despite normal haemoglobin levels, indicating long-term erythropoietic modulation. Despite these physiological changes, survivors reported minimal psychological morbidity, sharply contrasting with the post-recovery profiles of other viral haemorrhagic fevers. Stigma was prevalent during the outbreak; however, strong family support alleviated long-term psychosocial distress. Interpretation: Thirteen years post-infection, MVD survivors demonstrate multisystem physiological perturbations without marked psychological sequelae. These findings challenge assumptions of universal post-viral trauma and highlight the necessity for tailored survivor care models. Future longitudinal studies should investigate the mechanistic pathways underlying cardiometabolic and haematological reprogramming to inform intervention strategies in resource-limited settings.

23 October 2025 in Viruses
Verified
Journal Article
Open access
PDF file
RKRaymond Ernest Kaweesa
Raymond Ernest Kaweesa
Joseph Ssebwana KatendeJoseph Ssebwana Katende
Joseph Ssebwana Katende
GOGeoffrey Odoch
Geoffrey Odoch
ANAnnie Daphine Ntabadde
Annie Daphine Ntabadde
RWRaymond Reuel Wayesu
Raymond Reuel Wayesu
JSJennifer Serwanga
Jennifer Serwanga
Background: Despite repeated re-emergence of Sudan ebolavirus (SUDV), its long-term human toll remains under-characterised. We assessed multisystem clinical, biochemical, and psychosocial outcomes ~25 years after the 2000 Gulu outbreak. Methods: We conducted a cross-sectional evaluation of 45 survivors of laboratory-confirmed SUDV and 30 age- and gender-matched community controls from the same region. Symptoms were assessed as current at the study visit using a structured checklist; for each symptom present, we recorded severity and duration from onset to the visit date. Standardised clinical examinations, haematological and biochemical assessments, anxiety and depression screening, and structured interviews on social support and stigma were performed. Group comparisons were assessed with Wilcoxon rank-sum and χ2/Fisher’s exact tests; correlations were assessed with Spearman’s ρ. Findings: Core physiological indices (vital signs, BMI, blood pressure, and body temperature) and mental health were comparable between survivors and controls. Nevertheless, survivors reported ongoing symptoms, including joint pain and visual impairment each in 36% (16/45), fatigue in 18% (8/45), and neurological symptoms in 13% (6/45). Subclinical laboratory deviations centred on hepatic and platelet biology: elevated total bilirubin occurred in 14% of survivors versus 6.7% of controls; thrombocytopenia or platelet morphological abnormalities in 12% versus 3.3%; haemoglobin abnormalities in 6% versus 0%. Among survivors, albumin and mean platelet volume declined with age (both p ≤ 0.03). Psychological morbidity was low (normal anxiety 82% (37/45; and normal depression 80% (36/45). Yet a social paradox emerged, despite universal post-outbreak support, 98% (44/45) described enduring stigma. To minimise differential recall bias, symptom inventories were not collected from controls; consequently, between-group comparisons for symptom prevalence were not performed, and symptom inferences are restricted to survivors and framed descriptively. Interpretation: A quarter-century after infection, SUDV survivors show preserved systemic physiology but carry chronic musculoskeletal, sensory, and neurological sequelae, alongside a discrete subclinical profile implicating hepatic function and platelet biology. Psychological resilience coexists with near-universal, persistent stigma, indicating that material support did not achieve full psychosocial reintegration. Given the lack of virological and deep immune profiling, proposed pathogenetic mechanisms, such as antigen persistence or immune-mediated injury, remain speculative and hypotheses-generating only. These findings argue for survivor-centred long-term care, embedded with epidemic preparedness frameworks that integrate musculoskeletal rehabilitation, ophthalmic and neurological services with comprehensive mental health care, and sustained anti-stigma community engagement. This dissociation, including short-lived support alongside enduring stigma, indicates that humanitarian relief alone does not secure durable psychosocial reintegration and should be complemented by long-horizon, survivor-centred services and community engagement. Funding: This study was supported by the Coalition for Epidemic Preparedness Innovations (CEPI) under the Universal Protocol for Standardising Assays and Advancing Vaccine Immunogenicity Assessments for Emerging and Re-emerging Viral Threats, implemented through the Uganda Virus Research Institute (UVRI) as part of CEPI’s Centralised Laboratory Network (CLN).

24 June 2026 in Tropical Medicine and Health
Verified
Journal Article
Open access
RKRaymond Ernest Kaweesa
Raymond Ernest Kaweesa
BNBrenda Nairuba
Brenda Nairuba
GOGeoffrey Odoch
Geoffrey Odoch
RTRodney Abraham Tumusiime
Rodney Abraham Tumusiime
DMDeborah Mukisa
Deborah Mukisa
JSJennifer Serwanga
Jennifer Serwanga
Background: Mpox in people living with HIV (PLHIV) with advanced immunosuppression is poorly understood in sub-Saharan Africa, where high HIV prevalence intersects with limited access to mpox-specific antivirals. Urgent evidence is needed to guide clinical management and improve outcomes for this vulnerable population in resource-limited settings with outbreaks. Case presentation: We report a 30-year-old Ugandan man with advanced HIV (CD4 55 cells/µL, HIV-1 RNA 645,000 copies/mL) who presented with 2 weeks of widespread mucocutaneous disease, circumferential necrotic penile ulceration with severe dysuria, and periocular involvement. Mpox was confirmed by real-time PCR from multiple anatomical sites, with sequencing identifying Clade I (subclade Ib) infection. Longitudinal sampling showed consistently low Ct values in skin and genital lesions despite rising salivary Ct values, indicating differential compartmental viral clearance. Serial pus cultures from ulcerated lesions yielded multi-resistant gram-negative bacilli and coagulase-negative staphylococci, with sustained resistance to first-line agents throughout the clinical course. Meropenem remained the only antimicrobial to which isolates were consistently susceptible across all sampling points, suggestive of evolving polymicrobial wound colonisation under antibiotic selection pressure. Management and outcome: Empirical ceftriaxone and metronidazole proved ineffective. Culture-guided escalation to intravenous meropenem, along with intensive wound care, pain management, ocular prophylaxis, and resumption of antiretroviral therapy (ART), resulted in gradual clinical improvement. The patient was discharged after 4 weeks with healed skin lesions and mild residual ocular discomfort. At 3 months, immune reconstitution was observed (CD4 173 cells/µL; HIV-1 RNA 72 copies/mL) with complete functional recovery. Conclusions: Severe Clade Ib (subclade Ib) mpox in advanced HIV can present with genital necrosis, ocular involvement, persistent lesion-site viral burden, and multidrug-resistant bacterial superinfection. Even in the absence of specific antivirals, favourable outcomes can be achieved through integrated HIV care, early culture-guided antimicrobial stewardship, and proactive ocular management.

13 June 2025 in VeriXiv
Verified
Preprint
Open access
RKRaymond Ernest Kaweesa
Raymond Ernest Kaweesa
JKJoseph Ssebwana Katende
Joseph Ssebwana Katende
RWRaymond Reuel Wayesu
Raymond Reuel Wayesu
ANAnnie Daphine Ntabadde
Annie Daphine Ntabadde
SOSolomon Opio
Solomon Opio
RKRaymond Ernest Kaweesa
Raymond Ernest Kaweesa

7 July 2025 in VeriXiv
Verified
Preprint
Open access
RKRaymond Ernest Kaweesa
Raymond Ernest Kaweesa
RKRaymond Ernest Kaweesa
Raymond Ernest Kaweesa
JKJoseph Ssebwana Katende
Joseph Ssebwana Katende
GOGeoffrey Odoch
Geoffrey Odoch
RWRaymond Reuel Wayesu
Raymond Reuel Wayesu
PKPontiano Kaleebu
Pontiano Kaleebu

3 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
RKRaymond Ernest Kaweesa
Raymond Ernest Kaweesa
GOGeoffrey Odoch
Geoffrey Odoch
JSJennifer Serwanga
Jennifer Serwanga
SPSee Pdf
See Pdf
Background: Severe mpox in people living with HIV remains poorly characterised in African referral settings experiencing Clade 1b transmission. We investigated the clinical and biological features of critical illness during the 2025 Clade 1b mpox outbreak in Uganda. Methods: We conducted a prospective observational study nested within a consecutive cohort of 155 adults admitted to Entebbe Regional Referral Hospital, Uganda, with suspected or confirmed mpox between 3 March and 10 April 2025. Participants with predefined critical illness and laboratory-confirmed Clade 1b infection underwent compartment-specific mpox PCR testing, lesion bacterial culture with antimicrobial susceptibility testing, HIV viral load assessment, and routine haematology and biochemistry. Analyses were descriptive, given the small sample size and exploratory nature of the study. Findings: Ten of 155 hospitalised adults (6.5%) developed critical illness; four died, four had severe disease, and two required intensive care. All were people living with HIV. At approximately 14 days post-symptom onset, mpox DNA was consistently detected in skin, genital, and oral or saliva specimens with low cycle threshold values, whereas plasma detection was infrequent and occurred at higher values. Purulent lesion cultures were positive in 9/9 participants, yielding Gram-negative bacilli, Staphylococcus aureus, coagulase-negative staphylococci, and Enterococcus species, with broad resistance to commonly used antimicrobial classes; meropenem retained activity. Critically ill participants demonstrated an inflammatory profile with anaemia, neutrophilia with relative lymphopenia, hypoalbuminaemia, hyperbilirubinaemia, and elevated C-reactive protein. Survivors demonstrated near-complete viral clearance; one participant with persistent plasma and anal positivity died. Interpretation: Critical Clade 1b mpox was characterised by dominant mucocutaneous viral burden, frequent bacterial growth with antimicrobial resistance, and systemic inflammatory derangement in people with HIV, supporting integrated triage, antimicrobial stewardship, and inpatient management strategies.